Do analysts recommend XBIT or UPB?

Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 767.45%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts clearly believe Upstream Bio is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is XBIT or UPB more profitable?

XBiotech has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. XBiotech's return on equity of -31.62% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Upstream Bio -4,955.67% -48.40% -46.57%

Do analysts recommend ANIK or XBIT?

Anika Therapeutics presently has a consensus target price of $22.00, suggesting a potential upside of 8.64%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Anika Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer IMRX or XBIT?

Immuneering presently has a consensus price target of $15.71, suggesting a potential upside of 359.48%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, IMRX or XBIT?

Immuneering is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A XBiotech N/A N/A -$45.54M -$1.48 N/A

Is IMRX or XBIT more profitable?

Immuneering's return on equity of -27.15% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% XBiotech N/A -31.62% -30.29%

Do analysts rate XBIT or AKBA?

Akebia Therapeutics has a consensus target price of $3.90, suggesting a potential upside of 455.56%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Do analysts recommend XBIT or CAMP?

CAMP4 Therapeutics has a consensus target price of $10.86, suggesting a potential upside of 216.53%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CAMP4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

XBiotech (XBIT) Competitors

$2.16 0.00 (0.00%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$2.18 +0.02 (+0.93%)

As of 10/14/2026 04:10 PM Eastern

Compare

XBIT vs. UPB, ANIK, IMRX, AKBA, and CAMP

Should you buy XBiotech stock or one of its competitors? XBiotech's main competitors and comparable companies include Upstream Bio (UPB), Anika Therapeutics (ANIK), Immuneering (IMRX), Akebia Therapeutics (AKBA), and CAMP4 Therapeutics (CAMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XBiotech compare to Upstream Bio?

XBiotech (NASDAQ:XBIT) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Upstream Bio had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.79 beat Upstream Bio's score of 1.42 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
Upstream Bio	Positive

Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 767.45%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts clearly believe Upstream Bio is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

XBiotech has higher earnings, but lower revenue than Upstream Bio. XBiotech is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Upstream Bio	$2.85M	65.72	-$143.44M	-$2.90	N/A

XBiotech has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. XBiotech's return on equity of -31.62% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

55.7% of XBiotech shares are owned by institutional investors. 21.1% of XBiotech shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

XBiotech has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Summary

XBiotech beats Upstream Bio on 8 of the 14 factors compared between the two stocks.

How does XBiotech compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Anika Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
XBiotech	N/A	-31.62%	-30.29%

Anika Therapeutics has higher revenue and earnings than XBiotech. Anika Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.40	-$10.88M	-$0.27	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

Anika Therapeutics presently has a consensus target price of $22.00, suggesting a potential upside of 8.64%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Anika Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 21.1% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Anika Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.79 beat Anika Therapeutics' score of 1.44 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Anika Therapeutics	Positive
XBiotech	Very Positive

Summary

Anika Therapeutics beats XBiotech on 11 of the 15 factors compared between the two stocks.

How does XBiotech compare to Immuneering?

Immuneering (NASDAQ:IMRX) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Immuneering has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Immuneering is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

Immuneering's return on equity of -27.15% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
XBiotech	N/A	-31.62%	-30.29%

In the previous week, Immuneering had 2 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Immuneering and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.79 beat Immuneering's score of 1.05 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuneering	Positive
XBiotech	Very Positive

67.7% of Immuneering shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 14.9% of Immuneering shares are held by insiders. Comparatively, 21.1% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immuneering presently has a consensus price target of $15.71, suggesting a potential upside of 359.48%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Immuneering beats XBiotech on 9 of the 14 factors compared between the two stocks.

How does XBiotech compare to Akebia Therapeutics?

XBiotech (NASDAQ:XBIT) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

XBiotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. XBiotech's return on equity of -31.62% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 21.1% of XBiotech shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than XBiotech. Akebia Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Akebia Therapeutics	$236.20M	0.82	-$5.34M	-$0.11	N/A

In the previous week, Akebia Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Akebia Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.79 beat Akebia Therapeutics' score of 0.70 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
Akebia Therapeutics	Positive

Akebia Therapeutics has a consensus target price of $3.90, suggesting a potential upside of 455.56%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Akebia Therapeutics beats XBiotech on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to CAMP4 Therapeutics?

XBiotech (NASDAQ:XBIT) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

XBiotech has higher earnings, but lower revenue than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

In the previous week, CAMP4 Therapeutics had 4 more articles in the media than XBiotech. MarketBeat recorded 5 mentions for CAMP4 Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.79 beat CAMP4 Therapeutics' score of 0.48 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
CAMP4 Therapeutics	Neutral

55.7% of XBiotech shares are held by institutional investors. 21.1% of XBiotech shares are held by insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

XBiotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

CAMP4 Therapeutics has a consensus target price of $10.86, suggesting a potential upside of 216.53%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

XBiotech has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. XBiotech's return on equity of -31.62% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Summary

XBiotech beats CAMP4 Therapeutics on 8 of the 14 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$65.85M	$3.84B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-1.46	9.48	211.42	19.26
Price / Sales	N/A	1,168.88	565.60	77.58
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.47	16.54	10.51	5.92
Net Income	-$45.54M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-1.82%	-5.80%	-3.49%	-3.85%
1 Month Performance	-1.37%	-12.84%	-7.76%	-6.37%
1 Year Performance	-14.96%	3.05%	0.82%	-6.01%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	1.3886 of 5 stars	$2.16 flat	N/A	-13.9%	$65.85M	N/A	N/A	87	Positive News
UPB Upstream Bio	2.6817 of 5 stars	$4.59 -5.4%	$29.67 +546.3%	-82.9%	$265.64M	$3.16M	N/A	75	News Coverage Positive News
ANIK Anika Therapeutics	3.244 of 5 stars	$19.12 -3.1%	$22.00 +15.1%	+121.3%	$264.05M	$120.65M	N/A	235	Positive News
IMRX Immuneering	2.6851 of 5 stars	$3.83 -5.2%	$15.71 +310.3%	-42.6%	$261.38M	N/A	N/A	57	Positive News
AKBA Akebia Therapeutics	2.2684 of 5 stars	$0.88 -3.5%	$3.90 +343.9%	-74.8%	$252.30M	$236.20M	N/A	194	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. UPB, ANIK, IMRX, AKBA, and CAMP

How does XBiotech compare to Upstream Bio?

Summary

How does XBiotech compare to Anika Therapeutics?

Summary

How does XBiotech compare to Immuneering?

Summary

How does XBiotech compare to Akebia Therapeutics?

Summary

How does XBiotech compare to CAMP4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. UPB, ANIK, IMRX, AKBA, and CAMP

How does XBiotech compare to Upstream Bio?

Does the media favor XBIT or UPB?

Do analysts recommend XBIT or UPB?

Which has better valuation and earnings, XBIT or UPB?

Is XBIT or UPB more profitable?

Do insiders & institutionals have more ownership in XBIT or UPB?

Which has more risk & volatility, XBIT or UPB?

Summary

How does XBiotech compare to Anika Therapeutics?

Which has more risk & volatility, ANIK or XBIT?

Is ANIK or XBIT more profitable?

Which has higher earnings and valuation, ANIK or XBIT?

Do analysts recommend ANIK or XBIT?

Do institutionals and insiders hold more shares of ANIK or XBIT?

Does the media favor ANIK or XBIT?

Summary

How does XBiotech compare to Immuneering?

Which has more risk & volatility, IMRX or XBIT?

Which has better earnings and valuation, IMRX or XBIT?

Is IMRX or XBIT more profitable?

Does the media favor IMRX or XBIT?

Do insiders and institutionals have more ownership in IMRX or XBIT?

Do analysts prefer IMRX or XBIT?

Summary

How does XBiotech compare to Akebia Therapeutics?

Which has more risk & volatility, XBIT or AKBA?

Is XBIT or AKBA more profitable?

Do insiders and institutionals have more ownership in XBIT or AKBA?

Which has higher earnings and valuation, XBIT or AKBA?

Does the media favor XBIT or AKBA?

Do analysts rate XBIT or AKBA?

Summary

How does XBiotech compare to CAMP4 Therapeutics?

Which has preferable valuation and earnings, XBIT or CAMP?

Does the media refer more to XBIT or CAMP?

Do institutionals and insiders hold more shares of XBIT or CAMP?

Which has more volatility & risk, XBIT or CAMP?

Do analysts recommend XBIT or CAMP?

Is XBIT or CAMP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools